81 related articles for article (PubMed ID: 33072222)
1. Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.
Alagumuthu M; Rajpoot S; Baig MS
Cell Mol Bioeng; 2021 Apr; 14(2):177-185. PubMed ID: 33072222
[TBL] [Abstract][Full Text] [Related]
2. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
[TBL] [Abstract][Full Text] [Related]
4. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
5. Development and Evaluation of Peptidomimetic Compounds against SARS-CoV-2 Spike Protein: An in silico and in vitro Study.
Zarei O; Kleine-Weber H; Hoffmann M; Hamzeh-Mivehroud M
Mol Inform; 2022 Jul; 41(7):e2100231. PubMed ID: 35068079
[TBL] [Abstract][Full Text] [Related]
6. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
7. Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.
Morgan DC; Morris C; Mahindra A; Blair CM; Tejeda G; Herbert I; Turnbull ML; Lieber G; Willett BJ; Logan N; Smith B; Tobin AB; Bhella D; Baillie G; Jamieson AG
Pept Sci (Hoboken); 2021 Jul; 113(4):e24217. PubMed ID: 33615115
[TBL] [Abstract][Full Text] [Related]
8. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
11. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
12. Structural Dissection of Viral Spike-Protein Binding of SARS-CoV-2 and SARS-CoV-1 to the Human Angiotensin-Converting Enzyme 2 (ACE2) as Cellular Receptor.
Giordano D; De Masi L; Argenio MA; Facchiano A
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440241
[TBL] [Abstract][Full Text] [Related]
13. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
[TBL] [Abstract][Full Text] [Related]
15. Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface.
Bugatti K; Sartori A; Battistini L; Coppa C; Vanhulle E; Noppen S; Provinciael B; Naesens L; Stevaert A; Contini A; Vermeire K; Zanardi F
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240111
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis.
Khater I; Nassar A
Inform Med Unlocked; 2022; 29():100873. PubMed ID: 35136832
[TBL] [Abstract][Full Text] [Related]
17. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
18. A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD-ACE2 Interaction.
Fernandez-Fuentes N; Molina R; Oliva B
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769056
[TBL] [Abstract][Full Text] [Related]
19. Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein.
Tarek Ibrahim M; Tao P
J Biomol Struct Dyn; 2023; 41(15):7144-7157. PubMed ID: 36038961
[TBL] [Abstract][Full Text] [Related]
20. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
